Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Return to the main site

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Executive Briefing Series (formerly The Food & Drug Letter) > User Fee Law Corrects Funds Glitch for Generics and Biosimilars

Executive Briefing Series (formerly The Food & Drug Letter)

July 27, 2012

User Fee Law Corrects Funds Glitch for Generics and Biosimilars

P.L. 112-144, the new law reauthorizing user fees for prescription drugs, also creates new user fee programs for generics and biosimilars.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives

Related Articles

Hamburg Asks Congress to Shield User Fees from Sequestration PDUFA V Goals Deferred If ‘Cliff’ Talks Tank FDASIA Requires Some Changes to REMS Program Patient Participation, Labeling, Risk-Benefit Analysis in FDASIA

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.